Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Metrics to compare | ANRO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipANROPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.3x | −3.6x | −0.5x | |
PEG Ratio | −0.02 | 0.00 | 0.00 | |
Price/Book | 0.6x | 2.5x | 2.6x | |
Price / LTM Sales | - | 1.4x | 3.3x | |
Upside (Analyst Target) | 225.7% | 82.6% | 43.4% | |
Fair Value Upside | Unlock | 16.0% | 7.1% | Unlock |